As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

The former CEO of the collagen company is now leading Supergut, which plays in an emerging but competitive category of ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

Compounded Ozempic and Wegovy, cheaper generic versions of the weight-loss drugs, can no longer be sold. Doctor explains ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Behind the scenes, it ran real-time social listening to track sentiment and found discussions around GLP-1s rose 50% during ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

Jamie Mafdali of South Florida was hit with a cancer double-whammy three years ago. Shortly after her mother began treatment ...

A new study raises mental health concerns about popular weight loss drugs like Ozempic and Mounjaro. These GLP-1 agonists, while effective for appetite control, may disrupt dopamine pathways linked to ...